Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

doi:10.1001/jamaoncol.2015.4920

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

JAMA oncology - 1 Mar 2016

Gandara David R, Redman Mary, Hirsch Fred R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed

Identifiers

PMID: 26720042
DOI: 10.1001/jamaoncol.2015.4920

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.PMID 26720042Read ↗

Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE TrialSemantic proximity Read ↗

Navigating Through New, First-Line Treatment Options for Lung Cancer.Semantic proximity Read ↗

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).Semantic proximity Read ↗

Induction therapy for stage III lung cancer.Semantic proximity Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy in lung cancer: survival, quality of life improved for some patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.